Therapeutic drug monitoring of nifedipine by HPLC-MS/MS in treatment of arterial hypertension
Abstract
The method for the determination of nifedipine and dehydronifedipine in human serum for therapeutic drug monitoring in patients with arterial hypertension using HPLC-MS/MS was developed and validated. The study involved 42 patients taking nifedipine in the form of modified-release tablets. It has been shown that therapeutic drug monitoring of nifedipine is advisable to be performed both when administering dose of 30 mg (to identify patients needing to increase the dose of the drug to achieve the desired therapeutic effect), and when administering doses of 60 mg and 90 mg to identify patients with a high tendency to the development of side-effects. Simultaneous determination of nifedipine and dehydronifedipine in human serum allows to determine the phenotype of each patient according to the rate of nifedipine metabolism and to adjust the dose and the frequency of taking the drug depending on the intensity of biotransformation.
About the Authors
T. A. Rodina
ФГБУ «Научный центр экспертизы средств медицинского применения» Минздрава России
Russian Federation
Russian Federation
E. S. Melnikov
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России
Russian Federation
Russian Federation
S. A. Belkov
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России
Russian Federation
Russian Federation
A. A. Danko
ГБУЗ «Городская клиническая больница имени И.В. Давыдовского Департамента здравоохранения г. Москвы»
Russian Federation
Russian Federation
A. V. Sokolov
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России
Russian Federation
Russian Federation
A. B. Prokofiev
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России
Russian Federation
Russian Federation
References
1. Баймеева Н.В., Красных Л.М., Мирошниченко И.И. Мониторинг концентрации клозапина и норклозапина при терапии шизофрении // Ведомости Научного центра экспертизы средств медицинского применения. - 2016. - № 4. - С. 53-57.
2. Белова М.В., Ильяшенко К.К. Острые отравления препаратами, действующими преимущественно на сердечно-сосудистую систему // Токсикологический вестник. - 2016. - Т. 140. - № 5. - С. 31-35.
3. Кардиология: национальное руководство / Под ред. Ю.Н. Беленкова, Р.Г. Оганова. - М.: ГЭОТАР-Медиа. - 2007. - 1232 с.
4. Красных Л.М., Платова А.И., Баймеева Н.В., Василенко Г.Ф. Определение содержания клозапина и норклозапина в плазме крови методом тандемной масс-спектрометрии // Ведомости Научного центра экспертизы средств медицинского применения. - 2014. - № 1. - С. 27-31.
5. Руководство по экспертизе лекарственных средств / Под. ред. проф. А.Н. Миронова. - М.: Гриф и К. - 2013. - Т. 1. - 328 с.
6. Смирнов В.В., Егоренков Е.А., Красных Л.М., Василенко Г.Ф., Раменская Г.В. Определение активности ферментов метаболизма лекарственных средств - перспектива использования в клинической практике // Ведомости Научного центра экспертизы средств медицинского применения. - 2016. - № 4. - С. 28-32.
7. Baselt R.C. Disposition of toxic drugs and chemicals in man, 9 edn. Seal Beach: Biomedical Publications. - 2011.
8. Bortel L., et al. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure // Eur. J. of Clinical pharmacology. - 1989. - Т. 37. - No. 2. - Pp. 185-189.
9. Breimer D.D., Schellens J.H.M., Soons P.A. Nifedipine: variability in its kinetics and metabolism in man // Pharmacology & therapeutics. - 1989. - Т. 44. - No. 3. - Pp. 445-454.
10. Dias E., et al. An LC-MS assay for the screening of cardiovascular medications in human samples // J. of Chromatography B. - 2013. - Т. 937. - Pp. 44-53.
11. Gonzalez O., et al. Development of an LC-MS/MS method for the quantitation of 55 compounds prescribed in combined cardiovascular therapy // J. of Chromatography B. - 2011. - Т. 879. - No. 3. - Pp. 243-252.
12. Grigoriev A., et al. Development of a HPLC-MS/MS method for the simultaneous determination of nifedipine and lidocaine in human plasma // J. of Pharmaceutical and biomedical analysis. - 2016. - Т. 131. - Pp. 13-19.
13. Kallem R.R., et al. Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study // Biomedical Chromatography. - 2013. - Т. 27. - No. 3. - Pp. 349-355.
14. Kirsten R., Nelson K., Kirsten D., Heintz B. Clinical pharmacokinetics of vasodilators. Part I // Clin. Pharmacokinet. - 1998. - Т. 34. - Pp. 457-482.
15. Mancia G., et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. - 2013. - Т. 34. - No. 28. - Pp. 2159-2219.
16. Meredith P.A., Elliott H.L. A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS) // Integrated blood pressure control. - 2013. - Т. 6. - Pp. 79-87.
17. Pietta P., Rava A., Biondi P. High-performance liquid chromatography of nifedipine, its metabolites and photochemical degradation products // J. of Chromatography A. - 1981. - Т. 210. - No. 3. - Pp. 516-521.
18. Poole-Wilson P.A., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial // The Lancet. - 2004. - Т. 364. - No. 9437. - Pp. 849-857.
19. Raemsch K.D., Sommer J. Pharmacokinetics and metabolism of nifedipine // Hypertension. - 1983. - Т. 5. - No. 4. - Part 2. - P. 1118.
20. Rashid T.J., et al. Factors affecting the absolute bioavailability of nifedipine // Br. J. of Clinical pharmacology. - 1995. - Т. 40. - No. 1. - Pp. 51-58.
21. Toal C.B., et al. Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalat Canadian Trial (EXACT) // Clinical therapeutics. - 1997. - Т. 19. - No. 5. - Pp. 924-935.
22. Toal C.B. Formulation dependent pharmacokinetics - does the dosage form matter for nifedipine? // J. of Cardiovascular pharmacology. - 2004. - Т. 44. - No. 1. - Pp. 82-86.
23. Van der Nagel B.C.H., et al. High-throughput quantification of 8 antihypertensive drugs and active metabolites in human plasma using UPLC-MS/MS // J. of Chromatography B. - 2017. - Т. 1060. - Pp. 367-373.
24. Wang D., et al. Determination of nifedipine in human plasma by ultra-performance liquid chromatography - tandem mass spectrometry and its application in a pharmacokinetic study // J. of Chromatography B. - 2011. - Т. 879. - No. 20. - Pp. 1827-1832.
25. Zhou S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4 // Current drug metabolism. - 2008. - Т. 9. - No. 4. - Pp. 310-322.
Review
For citations:
Rodina T.A., Melnikov E.S., Belkov S.A., Danko A.A., Sokolov A.V., Prokofiev A.B. Therapeutic drug monitoring of nifedipine by HPLC-MS/MS in treatment of arterial hypertension. Journal Biomed. 2017;(4):53-69. (In Russ.)
Views:
502
Email this article 
